The Inflation Reduction Act permits Medicare to negotiate drug prices. Here's why the legislation is such a big deal for seniors.
California's Prop 61 faces strong opposition from the pharmaceutical industry, which has poured at least $109 million into defeating it.
At its core, l’affaire EpiPen is not about a single drug maker making sky’s-the-limit profits. It’s about how we pay for pharmaceuticals, how we contain price increases, and ultimately, who gets to use the drugs.
How one reporter "fell down a data rabbit hole" while investigating how many Medicaid patients were denied costly hep C drugs, and what she'll do differently next time.
